Back to News
Market Impact: 0.2
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Source: globenewswire.com
Healthcare & BiotechProduct Launches
The company is advancing its Phase 2 DURIPANC clinical study evaluating Ampligen's potential to reshape the tumor microenvironment and improve checkpoint-inhibitor efficacy. The update reinforces the broader clinical-development strategy but provides no trial efficacy, safety, enrollment, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search